Revelation Biosciences names Avance Clinical as CRO for Phase 2/3 Gemini AKI trial
REVB•Avance Clinical selected for Gemini AKI trial
Revelation Biosciences names Avance Clinical as CRO for Phase 2/3 Gemini AKI trial
- Revelation Biosciences selected Avance Clinical as contract research organization for its Phase 2/3 adaptive TITAN study of Gemini in acute kidney injury.
- Avance will run trial execution, including site operations, patient recruitment, safety oversight, data management, data quality, analysis.
- The company targets a study start later this year.
